UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial

Hepatology (Baltimore, Md.), 2022-04, Vol.75 (4), p.912-923

2022

Volltextzugriff (PDF)

Collagen biology and non‐invasive biomarkers of liver fibrosis

Liver international, 2020-04, Vol.40 (4), p.736-750

2020

Volltextzugriff (PDF)

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study

Clinical gastroenterology and hepatology, 2024-01, Vol.22 (1), p.102-112.e9

2024

Volltextzugriff (PDF)

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study

Clinical gastroenterology and hepatology, 2024-01, Vol.22 (1), p.113-123.e9

2024

Volltextzugriff (PDF)

The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participants

Expert opinion on investigational drugs, 2020-04, Vol.29 (4), p.411-422

2020

Volltextzugriff (PDF)

SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH

Hepatology communications, 2021-05, Vol.5 (5), p.760-773

2021

Volltextzugriff (PDF)

The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis

Contemporary clinical trials, 2021-05, Vol.104, p.106335-106335, Article 106335

2021

Volltextzugriff (PDF)

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti‐CD28 Domain Antibody Antagonist in Healthy Subjects

Journal of clinical pharmacology, 2017-02, Vol.57 (2), p.161-172

2017

Volltextzugriff (PDF)

The Target of Ezetimibe Is Niemann-Pick C1-Like 1 (NPC1L1)

Proceedings of the National Academy of Sciences - PNAS, 2005-06, Vol.102 (23), p.8132-8137

2005

Volltextzugriff (PDF)

Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis

JHEP reports, 2022-01, Vol.4 (1), p.100392-100392, Article 100392

2022

Volltextzugriff (PDF)

Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis

JHEP reports, 2021-08, Vol.3 (4), p.100317-100317, Article 100317

2021

Volltextzugriff (PDF)

PRO‐C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD

Hepatology communications, 2021-11, Vol.5 (11), p.1860-1872

2021

Volltextzugriff (PDF)

Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension

Bioorganic & medicinal chemistry letters, 2013-06, Vol.23 (12), p.3650-3653

2013

Volltextzugriff (PDF)

Deficiency in Inducible Nitric Oxide Synthase Results in Reduced Atherosclerosis in Apolipoprotein E-Deficient Mice

The Journal of immunology (1950), 2000-09, Vol.165 (6), p.3430-3435

2000

Volltextzugriff (PDF)

Optical Imaging Biomarkers of Drug-Induced Vascular Injury

Molecular imaging, 2015-01, Vol.14 (1), p.1-10

2015

Volltextzugriff (PDF)

Discovery and Clinical Evaluation of MK‐8150, A Novel Nitric Oxide Donor With a Unique Mechanism of Nitric Oxide Release

Journal of the American Heart Association, 2016-09, Vol.5 (9), p.n/a

2016

Volltextzugriff (PDF)

Cell Wall Alterations in the Arabidopsis emb30 Mutant

The Plant cell, 2000-11, Vol.12 (11), p.2047-2059

2000

Volltextzugriff (PDF)

Profiling and targeting connective tissue remodeling in autoimmunity - A novel paradigm for diagnosing and treating chronic diseases

Autoimmunity reviews, 2021-01, Vol.20 (1), p.102706, Article 102706

2021

Volltextzugriff (PDF)

Liver histopathology and extracellular matrix biomarkers in patients with advanced hepatic fibrosis from chronic hepatitis C who achieved a sustained virologic response

Journal of hepatology, 2020-08, Vol.73, p.S146

2020

Volltextzugriff (PDF)

THU009 - Liver histopathology and extracellular matrix biomarkers in patients with advanced hepatic fibrosis from chronic hepatitis C who achieved a sustained virologic response

Journal of hepatology, 2020-08, Vol.73, p.S146-S146

2020

Volltextzugriff (PDF)

LBP17 - BMS-986263 (novel targeted lipid nanoparticle delivering HSP47 siRNA) safety and target engagement in patients with advanced hepatic fibrosis: week 36 results from a phase 2 randomized, double-blind, placebo-controlled trial

Journal of hepatology, 2020-08, Vol.73, p.S132-S133

2020

Volltextzugriff (PDF)

BMS-986263 (novel targeted lipid nanoparticle delivering HSP47 siRNA) safety and target engagement in patients with advanced hepatic fibrosis: week 36 results from a phase 2 randomized, double-blind, placebo-controlled trial

Journal of hepatology, 2020-08, Vol.73, p.S132-S133

2020

Volltextzugriff (PDF)

Small molecule antagonists of complement receptor type 3 block adhesion and adhesion-dependent oxidative burst in human polymorphonuclear leukocytes

The Journal of pharmacology and experimental therapeutics, 2003-03, Vol.304 (3), p.1016-1024

2003

Volltextzugriff (PDF)

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects: Novel Anti-CD28 Domain Antibody Antagonist

Journal of clinical pharmacology, 2017-02, Vol.57 (2), p.161-172

2017

Volltextzugriff (PDF)

Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease Activity

Kidney international reports, 2020-11, Vol.5 (11), p.2021-2031

2020

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(41)
Dissertationen
(1)

Sprache

Englisch
(42)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial

Collagen biology and non‐invasive biomarkers of liver fibrosis

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study

The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participants

SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH

The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti‐CD28 Domain Antibody Antagonist in Healthy Subjects

The Target of Ezetimibe Is Niemann-Pick C1-Like 1 (NPC1L1)

Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis

Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis

PRO‐C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD

Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension

Deficiency in Inducible Nitric Oxide Synthase Results in Reduced Atherosclerosis in Apolipoprotein E-Deficient Mice

Optical Imaging Biomarkers of Drug-Induced Vascular Injury

Discovery and Clinical Evaluation of MK‐8150, A Novel Nitric Oxide Donor With a Unique Mechanism of Nitric Oxide Release

Cell Wall Alterations in the Arabidopsis emb30 Mutant

Profiling and targeting connective tissue remodeling in autoimmunity - A novel paradigm for diagnosing and treating chronic diseases

Liver histopathology and extracellular matrix biomarkers in patients with advanced hepatic fibrosis from chronic hepatitis C who achieved a sustained virologic response

THU009 - Liver histopathology and extracellular matrix biomarkers in patients with advanced hepatic fibrosis from chronic hepatitis C who achieved a sustained virologic response

LBP17 - BMS-986263 (novel targeted lipid nanoparticle delivering HSP47 siRNA) safety and target engagement in patients with advanced hepatic fibrosis: week 36 results from a phase 2 randomized, double-blind, placebo-controlled trial

BMS-986263 (novel targeted lipid nanoparticle delivering HSP47 siRNA) safety and target engagement in patients with advanced hepatic fibrosis: week 36 results from a phase 2 randomized, double-blind, placebo-controlled trial

Small molecule antagonists of complement receptor type 3 block adhesion and adhesion-dependent oxidative burst in human polymorphonuclear leukocytes

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects: Novel Anti-CD28 Domain Antibody Antagonist

Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease Activity

Suchergebnisse filtern